首页 > 最新文献

International Journal of Pharmaceutics最新文献

英文 中文
Light-responsive α-TOS liposomal nanocarriers Co-delivering TiO2 and doxorubicin for the treatment of breast cancer 光响应α-TOS脂质体纳米载体共递送TiO2和阿霉素治疗乳腺癌。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2025-12-31 DOI: 10.1016/j.ijpharm.2025.126552
Kaixin Feng , Zhongkun Zhang , Jingjing Zhang , Xiaohan Xia , Siyu Yao , Yufei Wang , Min Wu
Doxorubicin (DOX) is limited by its clinical toxicity as a breast cancer therapy. Traditional liposomal formulations improve the tumor delivery of DOX but suffer from inadequate controlled release and low encapsulation efficiency of DOX. To address these, we developed a photo-responsive liposomal formulation DTTPL by co-encapsulating DOX and TiO2 nanostructures (TiO2) within D-α-tocopheryl succinate (α-TOS)-PEG liposomes. DTTPL successfully facilitated the release of DOX through the light-sensitive catalysis mechanism of TiO2, exhibiting 4.6 times greater cytotoxicity against MCF-7 cells compared to free DOX. Transcriptional analysis revealed synergistic DOX/DTTPL dysregulation of key genes (Brca1, Bcl-2, Bax, Caspase-3), aligning with cytotoxicity. Eventually, light-triggered DOX/DTTPL formulation resulted in 70.09% of tumor growth inhibition (TGI) in mice with no significant organ toxicity. This photo-responsive nanoformulation enables efficient controlled release of DOX, offering an alternative strategy for small molecule delivery to treat triple negative breast cancer.
多柔比星(DOX)作为乳腺癌治疗的临床毒性受到限制。传统的脂质体制剂改善了DOX的肿瘤递送,但存在DOX控释不足和包封效率低的问题。为了解决这些问题,我们通过将DOX和TiO2纳米结构(TiO2)共包埋在D-α-生育酚琥珀酸酯(α-TOS)-PEG脂质体中,开发了光响应型脂质体DTTPL。DTTPL通过TiO2的光敏催化机制成功促进了DOX的释放,对MCF-7细胞的细胞毒性比游离DOX高4.6倍。转录分析显示DOX/DTTPL关键基因(Brca1、Bcl-2、Bax、Caspase-3)协同失调,与细胞毒性一致。最终,光触发DOX/DTTPL制剂在小鼠中产生70.09%的肿瘤生长抑制(TGI),没有明显的器官毒性。这种光响应纳米制剂能够有效地控制DOX的释放,为小分子递送治疗三阴性乳腺癌提供了一种替代策略。
{"title":"Light-responsive α-TOS liposomal nanocarriers Co-delivering TiO2 and doxorubicin for the treatment of breast cancer","authors":"Kaixin Feng ,&nbsp;Zhongkun Zhang ,&nbsp;Jingjing Zhang ,&nbsp;Xiaohan Xia ,&nbsp;Siyu Yao ,&nbsp;Yufei Wang ,&nbsp;Min Wu","doi":"10.1016/j.ijpharm.2025.126552","DOIUrl":"10.1016/j.ijpharm.2025.126552","url":null,"abstract":"<div><div>Doxorubicin (DOX) is limited by its clinical toxicity as a breast cancer therapy. Traditional liposomal formulations improve the tumor delivery of DOX but suffer from inadequate controlled release and low encapsulation efficiency of DOX. To address these, we developed a photo-responsive liposomal formulation DTTPL by co-encapsulating DOX and TiO<sub>2</sub> nanostructures (TiO<sub>2</sub>) within D-α-tocopheryl succinate (α-TOS)-PEG liposomes. DTTPL successfully facilitated the release of DOX through the light-sensitive catalysis mechanism of TiO<sub>2</sub>, exhibiting 4.6 times greater cytotoxicity against MCF-7 cells compared to free DOX. Transcriptional analysis revealed synergistic DOX/DTTPL dysregulation of key genes (Brca1, Bcl-2, Bax, Caspase-3), aligning with cytotoxicity.<!--> <!-->Eventually, light-triggered DOX/DTTPL formulation resulted in 70.09% of tumor growth inhibition (TGI) in mice with no significant organ toxicity. This photo-responsive nanoformulation enables efficient controlled release of DOX, offering an alternative strategy for small molecule delivery to treat triple negative breast cancer.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126552"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Poly (lactic-co-glycolic acid)-based microneedles for drug delivery across different biological barriers 基于聚(乳酸-羟基乙酸)的微针用于跨不同生物屏障的药物递送。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2025-12-28 DOI: 10.1016/j.ijpharm.2025.126529
Shelly Keisar , Qonita Kurnia Anjani , Abraham M. Abraham , Lalitkumar K. Vora , Eneko Larrañeta , Ryan F. Donnelly , Aiman Abu Ammar
Microneedles (MNs) are micro-sized needles that were originally designed as minimally invasive and painless devices capable of piercing the main skin barrier, the stratum corneum, without stimulating nerve fibers, showing promising prospects as an alternative to other drug administration routes. Poly (lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible copolymer with favorable mechanical properties, making it particularly suitable for fabrication of MNs for controlled-release drug delivery. This review provides a comprehensive overview of the design, fabrication, and therapeutic potential of PLGA-based MN systems across a broad range of applications, including transdermal systemic delivery, vaccine delivery and topical skin applications. Due to their exceptional virtues, PLGA MNs are further utilized in nontransdermal applications such as ocular, oral cavity, nasal, and other emerging uses that are presented. Eventually, toxicity and safety profile are discussed, and a concluding section on future perspectives is provided.
微针(MNs)是一种微型针头,最初被设计为微创和无痛的装置,能够刺穿皮肤的主要屏障角质层,而不刺激神经纤维,作为其他给药途径的替代方案,具有很好的前景。聚乳酸-羟基乙酸(PLGA)是一种生物可降解和生物相容性共聚物,具有良好的机械性能,特别适用于制造用于控释药物递送的纳米颗粒。这篇综述全面概述了基于plga的MN系统的设计、制造和治疗潜力,包括经皮全身递送、疫苗递送和局部皮肤应用。由于其特殊的优点,PLGA MNs进一步应用于非透皮应用,如眼、口腔、鼻和其他新兴用途。最后,讨论了毒性和安全性,并提供了对未来前景的总结部分。
{"title":"Poly (lactic-co-glycolic acid)-based microneedles for drug delivery across different biological barriers","authors":"Shelly Keisar ,&nbsp;Qonita Kurnia Anjani ,&nbsp;Abraham M. Abraham ,&nbsp;Lalitkumar K. Vora ,&nbsp;Eneko Larrañeta ,&nbsp;Ryan F. Donnelly ,&nbsp;Aiman Abu Ammar","doi":"10.1016/j.ijpharm.2025.126529","DOIUrl":"10.1016/j.ijpharm.2025.126529","url":null,"abstract":"<div><div>Microneedles (MNs) are micro-sized needles that were originally designed as minimally invasive and painless devices capable of piercing the main skin barrier, the <em>stratum corneum</em>, without stimulating nerve fibers, showing promising prospects as an alternative to other drug administration routes. Poly (lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible copolymer with favorable mechanical properties, making it particularly suitable for fabrication of MNs for controlled-release drug delivery. This review provides a comprehensive overview of the design, fabrication, and therapeutic potential of PLGA-based MN systems across a broad range of applications, including transdermal systemic delivery, vaccine delivery and topical skin applications. Due to their exceptional virtues, PLGA MNs are further utilized in nontransdermal applications such as ocular, oral cavity, nasal, and other emerging uses that are presented. Eventually, toxicity and safety profile are discussed, and a concluding section on future perspectives is provided.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126529"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation development of a dapivirine-releasing subdermal implant for HIV prevention 预防HIV的释放达匹韦林皮下植入物的配方开发。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2025-12-26 DOI: 10.1016/j.ijpharm.2025.126524
Siqi Wang, Rand Z. Murtadha, R. Karl Malcolm
There have been several significant advances in recent years around long-acting strategies for HIV pre-exposure prophylaxis, including DapiRing® (a 1-month dapivirine (DPV)-releasing vaginal ring), Apretude® (a cabotegravir intramuscular injection administered every two months), and Yeztugo® (a twice-yearly lenacapavir injection). With the goal of developing new drug delivery devices that can extend antiretroviral release for 12 months or longer, we report here our preliminary efforts to design a subdermal implant releasing the antiretroviral drug DPV. These reservoir-type rod implants (length 40 mm, cross-sectional diameters 2.5, 3.2, 3.5 or 4.0 mm) comprised a silicone elastomer core containing solid crystalline DPV (loading 10, 20 or 40 % w/w) and an open-ended non-medicated rate-controlling silicone elastomer membrane (thickness 0.5, 0.8 or 1.0 mm). DPV in vitro release rates could be modulated by adjusting the membrane thickness. Continuous in vitro DPV release ∼12 μg/day was demonstrated over 330 days, with sufficient residual drug content (∼87 mg/∼95 %) to extend release for at least 5 years. In particular, the study highlights the challenges in designing subdermal implants providing sufficient DPV release to maintain systemic/vaginal concentrations at protective levels.
近年来,在HIV暴露前预防的长效策略方面取得了一些重大进展,包括DapiRing®(1个月的达匹韦林(DPV)释放阴道环)、Apretude®(每两个月一次的卡博特韦肌肉注射)和Yeztugo®(每年两次的lenacapavir注射)。为了开发新的药物输送装置,使抗逆转录病毒释放延长12 个月或更长时间,我们在这里报告了我们设计一种释放抗逆转录病毒药物DPV的皮下植入物的初步努力。这些储层式抽油杆植入物(长度40 mm,横截面直径2.5、3.2、3.5或4.0 mm)由含有固体结晶DPV(载荷为10、20或40 % w/w)的硅弹性体芯和开放式非药物控制速率的硅弹性体膜(厚度0.5、0.8或1.0 mm)组成。DPV的体外释放速率可以通过调节膜厚度来调节。在330 天内,DPV连续体外释放~ 12 μg/天,具有足够的残留药物含量(~ 87 mg/ ~ 95 %),延长释放至少5 年。该研究特别强调了设计皮下植入物以提供足够的DPV释放以维持全身/阴道浓度在保护水平的挑战。
{"title":"Formulation development of a dapivirine-releasing subdermal implant for HIV prevention","authors":"Siqi Wang,&nbsp;Rand Z. Murtadha,&nbsp;R. Karl Malcolm","doi":"10.1016/j.ijpharm.2025.126524","DOIUrl":"10.1016/j.ijpharm.2025.126524","url":null,"abstract":"<div><div>There have been several significant advances in recent years around long-acting strategies for HIV pre-exposure prophylaxis, including DapiRing® (a 1-month dapivirine (DPV)-releasing vaginal ring), Apretude® (a cabotegravir intramuscular injection administered every two months), and Yeztugo® (a twice-yearly lenacapavir injection). With the goal of developing new drug delivery devices that can extend antiretroviral release for 12 months or longer, we report here our preliminary efforts to design a subdermal implant releasing the antiretroviral drug DPV. These reservoir-type rod implants (length 40 mm, cross-sectional diameters 2.5, 3.2, 3.5 or 4.0 mm) comprised a silicone elastomer core containing solid crystalline DPV (loading 10, 20 or 40 % w/w) and an open-ended non-medicated rate-controlling silicone elastomer membrane (thickness 0.5, 0.8 or 1.0 mm). DPV <em>in vitro</em> release rates could be modulated by adjusting the membrane thickness. Continuous <em>in vitro</em> DPV release ∼12 μg/day was demonstrated over 330 days, with sufficient residual drug content (∼87 mg/∼95 %) to extend release for at least 5 years. In particular, the study highlights the challenges in designing subdermal implants providing sufficient DPV release to maintain systemic/vaginal concentrations at protective levels.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126524"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cysteamine-eluting contact lenses: integrating in vitro, in vivo, and in silico approaches for ocular drug delivery 半胱氨酸洗脱隐形眼镜:整合体外、体内和计算机方法用于眼部药物输送。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2025-12-22 DOI: 10.1016/j.ijpharm.2025.126528
Anuj Chauhan , Sarbani Hazra , Brock Matter , Pankaj Kumar Sharma , Shilpa George , Aishee Dey , Bommanahalli Nagaraju Kumara , Uday B. Kompella
The objective of this study was to develop vitamin E nanobarrier contact lenses that can sustain the delivery of an equivalent amount of cysteamine to the cornea as eight drops per day regimen used in treating cystinosis. Senofilcon A lenses (14.0 mm diameter, −0.50 D power, 8.4 mm base curve) integrated with vitamin E and cysteamine were tested for drug release and fitted to the sink-release model to determine diffusivity and partition coefficient. The pharmacokinetics of cysteamine delivery by contact lenses and by control eye drops was measured in New Zealand white rabbits. Cysteamine delivery was modeled by a mechanistic model using contact lens parameters obtained from the in vitro studies along with known anatomical, physiological and drug specific parameters obtained from literature. The release duration of cysteamine increased from a few minutes in control lenses to about 2 and 6 h, in lenses loaded with 20 and 30 % vitamin E, respectively. In vivo studies showed that the contact lens-based approach can deliver significantly high concentrations compared to eye drops. The total mass of drug delivered by 20 % vitamin E loaded contact lens is more than six times the mass delivered by a single eye drop. The contact lens-based therapy achieves higher delivery than drops in the back of the eye tissues as well. The predictions of the mechanistic mathematical model are in good agreement with in vivo measurements for both eye drops and contact lenses. The contact lens-based delivery of cysteamine is a promising approach for replacing the multiple drop therapy.
这项研究的目的是开发维生素E纳米屏障隐形眼镜,这种隐形眼镜可以维持每天8滴等量的半胱胺到角膜,用于治疗胱氨酸病。将Senofilcon A透镜(直径14.0 mm, D功率-0.50,基曲线8.4 mm)与维生素E和半胱胺结合,进行药物释放测试,并拟合到沉淀释放模型以确定扩散系数和分配系数。研究了隐形眼镜和对照滴眼液给药半胱胺在新西兰大白兔体内的药代动力学。半胱胺的给药通过一个机制模型建模,该模型使用了从体外研究中获得的隐形眼镜参数以及从文献中获得的已知解剖、生理和药物特异性参数。在含有20%和30% %维生素E的晶状体中,半胱胺的释放时间分别从对照晶状体的几分钟增加到约2和6 h。体内研究表明,与滴眼液相比,基于隐形眼镜的方法可以提供明显更高的浓度。含有20% %维生素E的隐形眼镜所提供的药物总质量是一滴眼药水所提供的药物总质量的六倍多。这种基于隐形眼镜的疗法比在眼组织后面滴药的效果更好。机械数学模型的预测与眼药水和隐形眼镜的体内测量结果很好地一致。基于隐形眼镜的半胱胺递送是替代多次滴注治疗的一种有前途的方法。
{"title":"Cysteamine-eluting contact lenses: integrating in vitro, in vivo, and in silico approaches for ocular drug delivery","authors":"Anuj Chauhan ,&nbsp;Sarbani Hazra ,&nbsp;Brock Matter ,&nbsp;Pankaj Kumar Sharma ,&nbsp;Shilpa George ,&nbsp;Aishee Dey ,&nbsp;Bommanahalli Nagaraju Kumara ,&nbsp;Uday B. Kompella","doi":"10.1016/j.ijpharm.2025.126528","DOIUrl":"10.1016/j.ijpharm.2025.126528","url":null,"abstract":"<div><div>The objective of this study was to develop vitamin E nanobarrier contact lenses that can sustain the delivery of an equivalent amount of cysteamine to the cornea as eight drops per day regimen used in treating cystinosis. Senofilcon A lenses (14.0 mm diameter, −0.50 D power, 8.4 mm base curve) integrated with vitamin E and cysteamine were tested for drug release and fitted to the sink-release model to determine diffusivity and partition coefficient. The pharmacokinetics of cysteamine delivery by contact lenses and by control eye drops was measured in New Zealand white rabbits. Cysteamine delivery was modeled by a mechanistic model using contact lens parameters obtained from the in vitro studies along with known anatomical, physiological and drug specific parameters obtained from literature. The release duration of cysteamine increased from a few minutes in control lenses to about 2 and 6 h, in lenses loaded with 20 and 30 % vitamin E, respectively. In vivo studies showed that the contact lens-based approach can deliver significantly high concentrations compared to eye drops. The total mass of drug delivered by 20 % vitamin E loaded contact lens is more than six times the mass delivered by a single eye drop. The contact lens-based therapy achieves higher delivery than drops in the back of the eye tissues as well. The predictions of the mechanistic mathematical model are in good agreement with in vivo measurements for both eye drops and contact lenses. The contact lens-based delivery of cysteamine is a promising approach for replacing the multiple drop therapy.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126528"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alkaline phosphatase-triggered charge converting lipid nanoparticles: An innovative approach for oral nucleic acid delivery 碱性磷酸酶触发的电荷转化脂质纳米颗粒:一种口服核酸递送的创新方法。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2026-01-02 DOI: 10.1016/j.ijpharm.2026.126554
Ilaria Polidori , Leonie Iris Weber , Stefan Keim , Dennis To , Markus Hartl , Andreas Bernkop-Schnürch
Enzyme-responsive lipid nanoparticles (LNPs) offer a promising strategy for oral nucleic acid delivery to gastrointestinal tumors. We hypothesized that coating LNPs with polyphosphates (PP) would enhance mucus penetration and enable charge conversion upon activation by intestinal alkaline phosphatase (IAP). The presence of the cell-penetrating peptide (CPP) stearyl-D-Arg8 provides enhanced cellular uptake. LNPs were characterized regarding size, polydispersity index, zeta potential, charge conversion and evaluated for pH stability, behaviour in biorelevant fluids, and mucus diffusion. Plasmid DNA encoding for GFP or brain acid soluble protein-1 (BASP1) was encapsulated, and uptake and transfection were studied in intestinal cancer cell lines. Upon incubation with IAP, PP-coated D-Arg8-LNPs released phosphate groups and underwent charge conversion. These particles remained stable across pH 1.5–9.0 and were more resistant to biorelevant fluids, though destabilization occurred with digestive enzymes. Compared to DOTAP- and D-Arg8-LNPs, PP-coated LNPs showed superior mucus diffusion, cellular uptake, and transfection efficiency in hard-to-transfect Caco-2 and SW480 cells. Importantly, BASP1 expression from LNPs effectively suppressed SW480 proliferation. Overall, PP coated LNPs for oral administration can efficiently deliver nucleic acids into intestinal tumor cells, which may be suitable to interfere with the tumorigenic phenotype.
酶反应性脂质纳米颗粒(LNPs)为胃肠道肿瘤的口服核酸递送提供了一种很有前途的策略。我们假设用聚磷酸盐(PP)包裹LNPs可以增强黏液的渗透,并在肠道碱性磷酸酶(IAP)激活时实现电荷转换。细胞穿透肽(CPP) stearyl-D-Arg8的存在增强了细胞摄取。LNPs的特征包括大小、多分散性指数、zeta电位、电荷转换,以及pH稳定性、在生物相关流体中的行为和粘液扩散。包封编码GFP或脑酸溶蛋白-1 (BASP1)的质粒DNA,研究其在肠癌细胞系中的摄取和转染。经IAP孵育后,pp包被的D-Arg8-LNPs释放磷酸基团并进行电荷转换。这些颗粒在pH 1.5-9.0范围内保持稳定,并且对生物相关液体更具抵抗力,尽管消化酶会发生不稳定。与DOTAP-和D-Arg8-LNPs相比,pp包被的LNPs在难以转染的Caco-2和SW480细胞中表现出更好的粘液扩散、细胞摄取和转染效率。重要的是,来自LNPs的BASP1表达有效地抑制了SW480的增殖。综上所述,口服PP包被LNPs可以有效地将核酸传递到肠道肿瘤细胞中,可能适合干扰致瘤表型。
{"title":"Alkaline phosphatase-triggered charge converting lipid nanoparticles: An innovative approach for oral nucleic acid delivery","authors":"Ilaria Polidori ,&nbsp;Leonie Iris Weber ,&nbsp;Stefan Keim ,&nbsp;Dennis To ,&nbsp;Markus Hartl ,&nbsp;Andreas Bernkop-Schnürch","doi":"10.1016/j.ijpharm.2026.126554","DOIUrl":"10.1016/j.ijpharm.2026.126554","url":null,"abstract":"<div><div>Enzyme-responsive lipid nanoparticles (LNPs) offer a promising strategy for oral nucleic acid delivery to gastrointestinal tumors. We hypothesized that coating LNPs with polyphosphates (PP) would enhance mucus penetration and enable charge conversion upon activation by intestinal alkaline phosphatase (IAP). The presence of the cell-penetrating peptide (CPP) stearyl-D-Arg<sub>8</sub> provides enhanced cellular uptake. LNPs were characterized regarding size, polydispersity index, zeta potential, charge conversion and evaluated for pH stability, behaviour in biorelevant fluids, and mucus diffusion. Plasmid DNA encoding for GFP or brain acid soluble protein-1 (BASP1) was encapsulated, and uptake and transfection were studied in intestinal cancer cell lines. Upon incubation with IAP, PP-coated D-Arg<sub>8</sub>-LNPs released phosphate groups and underwent charge conversion. These particles remained stable across pH 1.5–9.0 and were more resistant to biorelevant fluids, though destabilization occurred with digestive enzymes. Compared to DOTAP- and D-Arg<sub>8</sub>-LNPs, PP-coated LNPs showed superior mucus diffusion, cellular uptake, and transfection efficiency in hard-to-transfect Caco-2 and SW480 cells. Importantly, BASP1 expression from LNPs effectively suppressed SW480 proliferation. Overall, PP coated LNPs for oral administration can efficiently deliver nucleic acids into intestinal tumor cells, which may be suitable to interfere with the tumorigenic phenotype.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126554"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An intelligent responsive ZIF-8 co-delivery nanoplatform with multimodal synergistic technologies for closed-loop therapy of tumors 基于多模态协同技术的智能响应ZIF-8共递送纳米平台,用于肿瘤闭环治疗。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2025-12-28 DOI: 10.1016/j.ijpharm.2025.126540
Siqi Chen, Yizhen Yan, Jiayi Zou, Xin He, Kexin Li
Multi-modal combination therapy for tumors can overcome the limitations of single-modal therapy and bring new opportunities for high-efficient tumor treatment. Nevertheless, how to ingeniously design functionalized nanocarriers to mediate the synergistict effects among various therapeutic approaches remains a core challenge. In this study, we developed a polydopamine (PDA) coated outside and glucose oxidase (GOx) adsorbed inside copper-doped zeolitic imidazolate framework-8 (CZ8) with metformin hydrochloride (MET) / doxorubicin (DOX) as a multifunctional nano-codelivery system, abbreviated as PMDGCZ8, which could focus more on the synergy and continuity of multiple therapies including photothermal therapy (PTT), chemodynamic therapy (CDT), starving tumor therapy (STT) and chemotherapy (CT). Herein, PMDGCZ8 innovatively combined the gating effect of PDA membrane with the pH sensitivity of CZ8 skeleton to form a dual-responsive bomb that could trigger release on demand and significantly improve the accuracy of tumor localization. Furthermore, we also incorporated the strategies of reshaping the tumor hypoxia and immunosuppressive microenvironment into the synergistic treatment process in order to achieve a comprehensive anti-tumor ecological network. Both in vitro and in vivo experiments suggested that PMDGCZ8 significantly enhanced drug accumulation on tumors, reduced systemic toxicity, activated anti-tumor immune response, further inhibited the recurrence and metastasis, and consequently was expected to become a new type of nano-delivery platform with great development potential.
肿瘤多模式联合治疗可以克服单模式治疗的局限性,为肿瘤的高效治疗带来新的机遇。然而,如何巧妙地设计功能化纳米载体来介导各种治疗方法之间的协同作用仍然是一个核心挑战。在本研究中,我们开发了一种聚多巴胺(PDA)包被,葡萄糖氧化酶(GOx)吸附在铜掺杂的咪唑酸分子体框架-8 (CZ8)内,与盐酸二甲双胍(MET) /多柔比星(DOX)作为多功能纳米共递送系统,简称PMDGCZ8,它可以更多地关注光热治疗(PTT)、化学动力学治疗(CDT)、饥饿肿瘤治疗(STT)和化疗(CT)等多种治疗的协同作用和连续性。本研究中,PMDGCZ8创新性地将PDA膜的门控效应与CZ8骨架的pH敏感性结合起来,形成双响应炸弹,可按需触发释放,显著提高肿瘤定位的准确性。此外,我们还将重塑肿瘤缺氧和免疫抑制微环境的策略纳入协同治疗过程,以实现全面的抗肿瘤生态网络。体外和体内实验均表明,PMDGCZ8可显著增强药物在肿瘤上的蓄积,降低全身毒性,激活抗肿瘤免疫反应,进一步抑制肿瘤的复发和转移,有望成为一种具有巨大开发潜力的新型纳米给药平台。
{"title":"An intelligent responsive ZIF-8 co-delivery nanoplatform with multimodal synergistic technologies for closed-loop therapy of tumors","authors":"Siqi Chen,&nbsp;Yizhen Yan,&nbsp;Jiayi Zou,&nbsp;Xin He,&nbsp;Kexin Li","doi":"10.1016/j.ijpharm.2025.126540","DOIUrl":"10.1016/j.ijpharm.2025.126540","url":null,"abstract":"<div><div>Multi-modal combination therapy for tumors can overcome the limitations of single-modal therapy and bring new opportunities for high-efficient tumor treatment. Nevertheless, how to ingeniously design functionalized nanocarriers to mediate the synergistict effects among various therapeutic approaches remains a core challenge. In this study, we developed a polydopamine (PDA) coated outside and glucose oxidase (GOx) adsorbed inside copper-doped zeolitic imidazolate framework-8 (CZ8) with metformin hydrochloride (MET) / doxorubicin (DOX) as a multifunctional nano-codelivery system, abbreviated as PMDGCZ8, which could focus more on the synergy and continuity of multiple therapies including photothermal therapy (PTT), chemodynamic therapy (CDT), starving tumor therapy (STT) and chemotherapy (CT). Herein, PMDGCZ8 innovatively combined the gating effect of PDA membrane with the pH sensitivity of CZ8 skeleton to form a dual-responsive bomb that could trigger release on demand and significantly improve the accuracy of tumor localization. Furthermore, we also incorporated the strategies of reshaping the tumor hypoxia and immunosuppressive microenvironment into the synergistic treatment process in order to achieve a comprehensive anti-tumor ecological network. Both in vitro and <em>in vivo</em> experiments suggested that PMDGCZ8 significantly enhanced drug accumulation on tumors, reduced systemic toxicity, activated anti-tumor immune response, further inhibited the recurrence and metastasis, and consequently was expected to become a new type of nano-delivery platform with great development potential.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126540"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A commercial-scale high-throughput near-infrared transmission spectroscopy system for full inspection of active pharmaceutical ingredient content in all tablets 一种商业规模的高通量近红外透射光谱系统,用于全面检查所有片剂中的活性药物成分含量。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2025-12-21 DOI: 10.1016/j.ijpharm.2025.126516
Junki Sahara , Katsuhiko Nishiyama , Kazuki Shinoyama , Aya Ikarashi , Takuma Yokoyama , Shinya Matsuda , Kenji Yoshii , Masaya Fujimoto , Yasufumi Yagisawa , Koji Nakayama , Tomoaki Sakamoto
Near-infrared (NIR) spectroscopy is a nondestructive analytical technique that is increasingly considered for inclusion in Process Analytical Technology (PAT) frameworks and for 100% inspection, with the potential to raise pharmaceutical product quality. While reflectance-based NIR systems already deliver throughputs suitable for commercial manufacturing, transmission-based NIR systems, although offering superior predictive accuracy for active pharmaceutical ingredient (API) content in tablets, have been throughput-limited. Recently, a newly developed transmission NIR spectrometer has been shown to acquire precise tablet spectra within a few milliseconds. In this study, a spectrometer was integrated into a belt-conveyor transport apparatus to create a high-throughput analytical system for pharmaceutical tablets. A throughput of 186,000 tablets per hour was achieved, demonstrating 100% API content measurement and real-time rejection of out-of-specification tablets.
近红外(NIR)光谱是一种无损分析技术,越来越多地被考虑纳入过程分析技术(PAT)框架和100%检查,具有提高药品质量的潜力。虽然基于反射的近红外系统已经提供了适合商业生产的吞吐量,但基于透射的近红外系统虽然对片剂中的活性药物成分(API)含量提供了卓越的预测准确性,但吞吐量有限。最近,一种新开发的透射式近红外光谱仪已被证明可以在几毫秒内获得精确的片剂光谱。在本研究中,将光谱仪集成到带式输送机输送装置中,以创建高通量的片剂分析系统。实现了186,000片/小时的吞吐量,证明了100%的API含量测量和不合格片剂的实时剔除。
{"title":"A commercial-scale high-throughput near-infrared transmission spectroscopy system for full inspection of active pharmaceutical ingredient content in all tablets","authors":"Junki Sahara ,&nbsp;Katsuhiko Nishiyama ,&nbsp;Kazuki Shinoyama ,&nbsp;Aya Ikarashi ,&nbsp;Takuma Yokoyama ,&nbsp;Shinya Matsuda ,&nbsp;Kenji Yoshii ,&nbsp;Masaya Fujimoto ,&nbsp;Yasufumi Yagisawa ,&nbsp;Koji Nakayama ,&nbsp;Tomoaki Sakamoto","doi":"10.1016/j.ijpharm.2025.126516","DOIUrl":"10.1016/j.ijpharm.2025.126516","url":null,"abstract":"<div><div>Near-infrared (NIR) spectroscopy is a nondestructive analytical technique that is increasingly considered for inclusion in Process Analytical Technology (PAT) frameworks and for 100% inspection, with the potential to raise pharmaceutical product quality. While reflectance-based NIR systems already deliver throughputs suitable for commercial manufacturing, transmission-based NIR systems, although offering superior predictive accuracy for active pharmaceutical ingredient (API) content in tablets, have been throughput-limited. Recently, a newly developed transmission NIR spectrometer has been shown to acquire precise tablet spectra within a few milliseconds. In this study, a spectrometer was integrated into a belt-conveyor transport apparatus to create a high-throughput analytical system for pharmaceutical tablets. A throughput of 186,000 tablets per hour was achieved, demonstrating 100% API content measurement and real-time rejection of out-of-specification tablets.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126516"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ERAP2 inhibitor −incorporated nanofibers: Characterization and biological assessment ERAP2抑制剂纳米纤维:表征和生物学评价。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2026-01-02 DOI: 10.1016/j.ijpharm.2026.126555
Filipa Vasconcelos , Laetitia Lesire , Adrien Herledan , Catherine Piveteau , Benoit Deprez , Hermis Iatrou , Rebecca Deprez-Poulain
ERAP2 is an enzyme essential in the preparation of mature antigen from peptide precursors. Inhibitors of this enzyme can find applications in immuno-oncology and in the treatment of autoimmune diseases including psoriasis and ankylosing spondylitis. In recent years, electrospinning has attracted considerable interest in the field of drug delivery. The potential applications of electrospun fibers in the treatment of skin and arthritis diseases are significant. This can be attributed to the fibers’ structural similarity to the extracellular matrix, in addition to their capacity to encapsulate disease-modifying anti-inflammatory agents. Electrospun fibrous mats are also used as drug delivery systems for loading potential anticancer drugs, with the aim of killing cancer cells. This allows for enhanced tumour penetration, increased drug retention, and higher drug delivery.
The objective of this project was to evaluate the production of meshes using electrospun poly(ε-Caprolactone) (PCL), and poly-(vinyl alcohol) (PVA) fibrous patches, loaded with an ERAP2 inhibitor, with or without liposomes. An examination was conducted to ascertain the physicochemical properties, including morphology and structure. The loading, release and stability of the inhibitor was studied by both UV–Vis and MS spectroscopy. The cytotoxic assay demonstrated the biocompatibility of the fabricated nanomats of PVA and PVA-liposome (PVA-L) formulations. In vitro assays demonstrated the compatibility of meshes with cell growth, ERAP2 engagement and antigen presentation. The results of the study validated the potential for future applications in the specified therapeutic areas.
ERAP2是肽前体制备成熟抗原所必需的酶。这种酶的抑制剂可以在免疫肿瘤学和自身免疫性疾病(包括牛皮癣和强直性脊柱炎)的治疗中找到应用。近年来,静电纺丝技术在药物输送领域引起了广泛的关注。电纺纤维在皮肤和关节炎疾病治疗中的潜在应用是重要的。这可以归因于纤维的结构与细胞外基质的相似性,以及它们包裹疾病改善抗炎剂的能力。电纺纤维垫也被用作药物输送系统,用于装载潜在的抗癌药物,目的是杀死癌细胞。这允许增强肿瘤穿透,增加药物潴留和更高的药物递送。本项目的目的是评估使用负载ERAP2抑制剂的电纺丝聚(ε-己内酯)(PCL)和聚乙烯醇(PVA)纤维片(含或不含脂质体)生产网的效果。进行了检查,以确定物理化学性质,包括形态和结构。通过紫外可见光谱和质谱分析研究了该缓蚀剂的负载、释放和稳定性。细胞毒性实验证明了聚乙烯醇和聚乙烯醇脂质体(PVA- l)制剂制备的纳米粒的生物相容性。体外实验证明了网状物与细胞生长、ERAP2结合和抗原呈递的相容性。研究结果验证了在特定治疗领域未来应用的潜力。
{"title":"ERAP2 inhibitor −incorporated nanofibers: Characterization and biological assessment","authors":"Filipa Vasconcelos ,&nbsp;Laetitia Lesire ,&nbsp;Adrien Herledan ,&nbsp;Catherine Piveteau ,&nbsp;Benoit Deprez ,&nbsp;Hermis Iatrou ,&nbsp;Rebecca Deprez-Poulain","doi":"10.1016/j.ijpharm.2026.126555","DOIUrl":"10.1016/j.ijpharm.2026.126555","url":null,"abstract":"<div><div>ERAP2 is an enzyme essential in the preparation of mature antigen from peptide precursors. Inhibitors of this enzyme can find applications in immuno-oncology and in the treatment of autoimmune diseases including psoriasis and ankylosing spondylitis. In recent years, electrospinning has attracted considerable interest in the field of drug delivery. The potential applications of electrospun fibers in the treatment of skin and arthritis diseases are significant. This can be attributed to the fibers’ structural similarity to the extracellular matrix, in addition to their capacity to encapsulate disease-modifying anti-inflammatory agents. Electrospun fibrous mats are also used as drug delivery systems for loading potential anticancer drugs, with the aim of killing cancer cells. This allows for enhanced tumour penetration, increased drug retention, and higher drug delivery.</div><div>The objective of this project was to evaluate the production of meshes using electrospun poly(ε-Caprolactone) (PCL), and poly-(vinyl alcohol) (PVA) fibrous patches, loaded with an ERAP2 inhibitor, with or without liposomes. An examination was conducted to ascertain the physicochemical properties, including morphology and structure. The loading, release and stability of the inhibitor was studied by both UV–Vis and MS spectroscopy. The cytotoxic assay demonstrated the biocompatibility of the fabricated nanomats of PVA and PVA-liposome (PVA-L) formulations. <em>In vitro</em> assays demonstrated the compatibility of meshes with cell growth, ERAP2 engagement and antigen presentation. The results of the study validated the potential for future applications in the specified therapeutic areas.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126555"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The nanoparticle protein corona impacts interactions with monocytes and macrophages 纳米颗粒蛋白冠影响与单核细胞和巨噬细胞的相互作用。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2025-12-20 DOI: 10.1016/j.ijpharm.2025.126518
Anika Lins , Marco Fortmann , Dennis Mulac-Hahnen , Hans-Ulrich Humpf , Klaus Langer
This study demonstrates that both the presence and the type of the protein corona have a high impact on the interactions of nanoparticles with cells of the mononuclear phagocyte system. Nanoparticles with an opsonin-rich protein corona are rapidly recognized and taken up by these cells. This results in the clearance of nanoparticles from the bloodstream and their accumulation in liver and spleen. To gain deeper insights into this phenomenon, the protein corona was analyzed using mass spectrometry. Furthermore, nanoparticle interactions with THP-1 monocytes and macrophage-like cells derived from THP-1 monocytes were investigated using fluorescence microscopy and flow cytometry. Specifically, we examined the following aspects: (I) the duration of nanoparticle incubation with immune cells, (II) the type of the protein corona formed, (III) the type of immune cells used, and (IV) the medium used for nanoparticle incubation. We demonstrated that the composition of the hard protein corona, and especially the strength of the enrichment of opsonins, is a key determinant of nanoparticle interaction with immune cells, highlighting the importance of protein corona analysis.
本研究表明,蛋白冠的存在和类型对纳米颗粒与单核吞噬细胞系统细胞的相互作用有很大的影响。具有富含调理素蛋白冠的纳米颗粒被这些细胞迅速识别并吸收。这导致纳米颗粒从血液中清除,并在肝脏和脾脏中积聚。为了更深入地了解这一现象,使用质谱分析了蛋白质冠。此外,利用荧光显微镜和流式细胞术研究纳米颗粒与THP-1单核细胞和THP-1单核细胞衍生的巨噬细胞样细胞的相互作用。具体来说,我们研究了以下几个方面:(I)纳米颗粒与免疫细胞孵育的持续时间,(II)形成的蛋白质冠的类型,(III)使用的免疫细胞类型,以及(IV)用于纳米颗粒孵育的培养基。我们证明了硬蛋白电晕的组成,特别是调理素富集的强度,是纳米颗粒与免疫细胞相互作用的关键决定因素,突出了蛋白电晕分析的重要性。
{"title":"The nanoparticle protein corona impacts interactions with monocytes and macrophages","authors":"Anika Lins ,&nbsp;Marco Fortmann ,&nbsp;Dennis Mulac-Hahnen ,&nbsp;Hans-Ulrich Humpf ,&nbsp;Klaus Langer","doi":"10.1016/j.ijpharm.2025.126518","DOIUrl":"10.1016/j.ijpharm.2025.126518","url":null,"abstract":"<div><div>This study demonstrates that both the presence and the type of the protein corona have a high impact on the interactions of nanoparticles with cells of the mononuclear phagocyte system. Nanoparticles with an opsonin-rich protein corona are rapidly recognized and taken up by these cells. This results in the clearance of nanoparticles from the bloodstream and their accumulation in liver and spleen. To gain deeper insights into this phenomenon, the protein corona was analyzed using mass spectrometry. Furthermore, nanoparticle interactions with THP-1 monocytes and macrophage-like cells derived from THP-1 monocytes were investigated using fluorescence microscopy and flow cytometry. Specifically, we examined the following aspects: (I) the duration of nanoparticle incubation with immune cells, (II) the type of the protein corona formed, (III) the type of immune cells used, and (IV) the medium used for nanoparticle incubation. We demonstrated that the composition of the hard protein corona, and especially the strength of the enrichment of opsonins, is a key determinant of nanoparticle interaction with immune cells, highlighting the importance of protein corona analysis.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126518"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oleosomes as emerging Next-Generation carrier for topical drug delivery 油质体作为外用药物递送的新一代载体。
IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-10 Epub Date: 2026-01-03 DOI: 10.1016/j.ijpharm.2025.126545
Sumel Ashique , Biplab Debnath , Shayeri Chatterjee Ganguly , Piyali Khamkat , Priya Manna , Md Sadique Hussain , Mohini Mondal , Tahreen Taj , Hitesh Chopra , Sabina Yasmin , Juberahamad Rajjak Attar , Md Yousuf Ansari
Oleosomes are natural oil bodies extracted from plant seeds and are becoming promising candidates for topical drug-delivery carriers because of their unique structure, biocompatibility, and sustainable nature. This study primarily focuses on exploring the potential of oleosomes with regard to their structural characteristics, extraction strategies, loading approaches, release mechanisms, and their wide range of applications compared with other carrier systems. Current challenges such as the low loading capacity for hydrophilic drugs, lack of regulatory standardization, and allergenicity are being addressed through evolving approaches including hybrid oleosome-liposome systems, recombinant oleosin engineering, and stimulus-responsive coatings. Marketed products and patents further emphasize the translational applicability of oleosome technology. Altogether, oleosomes represent an emerging, environmentally friendly platform for novel topical and transdermal drug delivery systems. These oleosomes are progressing as a multipurpose and scalable platform with significant potential for food, cosmetic, and pharmaceutical applications. From versatile natural emulsions to precision-targeted drug carriers, forthcoming research is converging toward strategies to advance oleosome technology. One such evolving direction is the synthetic molecular biology application to engineer “designer” oleosomes.
油质体是从植物种子中提取的天然油体,因其独特的结构、生物相容性和可持续性而成为局部药物递送载体的有希望的候选者。本研究主要探讨了油脂体的结构特征、提取策略、装载方式、释放机制以及与其他载体体系相比的广泛应用前景。进一步的挑战是低负载亲水性药物容量,缺乏监管标准化,以及过敏原性,正在通过诸如混合油质体-脂质体系统,重组油蛋白工程和刺激响应涂层等不断发展的方法来解决。市场上的产品和专利进一步强调了油质体技术的转化适用性。总之,油质体代表了一种新兴的,环境友好的平台,用于新的局部和透皮给药系统。这些油脂体作为一种多用途、可扩展的平台,在食品、化妆品和制药领域具有重要的潜力。从多功能的天然乳剂到精确靶向的药物载体,未来的研究正在趋向于提高油质体的有利方法。其中一个发展方向是应用合成分子生物学来设计“设计”油体。
{"title":"Oleosomes as emerging Next-Generation carrier for topical drug delivery","authors":"Sumel Ashique ,&nbsp;Biplab Debnath ,&nbsp;Shayeri Chatterjee Ganguly ,&nbsp;Piyali Khamkat ,&nbsp;Priya Manna ,&nbsp;Md Sadique Hussain ,&nbsp;Mohini Mondal ,&nbsp;Tahreen Taj ,&nbsp;Hitesh Chopra ,&nbsp;Sabina Yasmin ,&nbsp;Juberahamad Rajjak Attar ,&nbsp;Md Yousuf Ansari","doi":"10.1016/j.ijpharm.2025.126545","DOIUrl":"10.1016/j.ijpharm.2025.126545","url":null,"abstract":"<div><div>Oleosomes are natural oil bodies extracted from plant seeds and are becoming promising candidates for topical drug-delivery carriers because of their unique structure, biocompatibility, and sustainable nature. This study primarily focuses on exploring the potential of oleosomes with regard to their structural characteristics, extraction strategies, loading approaches, release mechanisms, and their wide range of applications compared with other carrier systems. Current challenges such as the low loading capacity for hydrophilic drugs, lack of regulatory standardization, and allergenicity are being addressed through evolving approaches including hybrid oleosome-liposome systems, recombinant oleosin engineering, and stimulus-responsive coatings. Marketed products and patents further emphasize the translational applicability of oleosome technology. Altogether, oleosomes represent an emerging, environmentally friendly platform for novel topical and transdermal drug delivery systems. These oleosomes are progressing as a multipurpose and scalable platform with significant potential for food, cosmetic, and pharmaceutical applications. From versatile natural emulsions to precision-targeted drug carriers, forthcoming research is converging toward strategies to advance oleosome technology. One such evolving direction is the synthetic molecular biology application to engineer “designer” oleosomes.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"690 ","pages":"Article 126545"},"PeriodicalIF":5.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Pharmaceutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1